Kestra Private Wealth Services LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Kestra Private Wealth Services LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,472 shares of the company’s stock after acquiring an additional 908 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Eli Lilly and Company were worth $17,180,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $26,000. Thompson Investment Management Inc. purchased a new position in Eli Lilly and Company during the 3rd quarter worth $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company in the third quarter valued at $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the third quarter valued at $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at about $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.5 %

Shares of Eli Lilly and Company stock traded up $3.82 during trading hours on Monday, reaching $737.33. 2,726,536 shares of the company’s stock were exchanged, compared to its average volume of 3,017,770. The firm has a market capitalization of $700.58 billion, a price-to-earnings ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52-week low of $392.26 and a 52-week high of $800.78. The company has a fifty day moving average of $760.89 and a 200-day moving average of $668.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.09 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.